- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dry Eye
- Interventions
- Systane Complete PF, Refresh Relieva PF, Refresh Optive Mega-3 PF, CVS Health Lubricant Eye Drop (PG 0.6%)
- Drug
- Lead sponsor
- University of California, Berkeley
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Berkeley, California
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
- Drug
- Lead sponsor
- Othera Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 5
- States / cities
- Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Faricimab, Ranibizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 60
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fullerton, California + 53 more
- Conditions
- Health Behavior, Health Care Utilization
- Interventions
- Phase II Promotores de Salud, Phase I Promotores de Salud Outreach
- Behavioral
- Lead sponsor
- University of Oregon
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 1,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Eugene, Oregon
- Conditions
- Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
- Interventions
- Dronabinol Capsules, Placebo
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- Hosuton, Texas • Houston, Texas
- Conditions
- Keratoconus
- Interventions
- Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment
- Combination Product
- Lead sponsor
- Epion Therapeutics
- Industry
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Murrieta, California + 9 more
- Conditions
- Non-Infectious Anterior Uveitis
- Interventions
- 8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops
- Drug
- Lead sponsor
- Aciont Inc
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more
- Conditions
- Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
- Interventions
- Arginine hydrochloride, Sodium Chloride 0.9%
- Drug
- Lead sponsor
- David K Carroll
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Postoperative Pain, Acute
- Interventions
- Active Pulsed Shortwave Treatment with BioElectronics Model 088, Sham Treatment
- Device
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Primary Open-Angle Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost, Timolol 0.5%, Placebo Eye Drops, Placebo Ocular Insert
- Drug · Device
- Lead sponsor
- ForSight Vision5, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 10
- States / cities
- Artesia, California • La Jolla, California • Newport Beach, California + 7 more
- Conditions
- Dry Eye Syndromes, Keratoconjunctivitis Sicca
- Interventions
- KPI-121, Placebo
- Drug
- Lead sponsor
- Kala Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 11
- States / cities
- Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more
- Conditions
- Body Image, Eating Disorder Symptom
- Interventions
- EVERYbody Project, Video + Expressive Writing
- Behavioral · Other
- Lead sponsor
- Western Washington University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 141 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Bellingham, Washington
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Inhaled Nitric Oxide
- Drug
- Lead sponsor
- Geno LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Pittsburgh, Pennsylvania
- Conditions
- Diabetic Retinopathy, Diabetic Macular Edema, NPDR - Non Proliferative Diabetic Retinopathy, PDR - Proliferative Diabetic Retinopathy
- Interventions
- APX3330, Placebo
- Drug
- Lead sponsor
- Ocuphire Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 20 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- UBX1325, Sham
- Drug · Other
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Bakersfield, California • Encino, California + 15 more
- Conditions
- Mask Ventilation, Airway Obstruction Upper, Airway Management
- Interventions
- Articulated Oral Airway, Guedel oral airway (active comparator)
- Device
- Lead sponsor
- Ron Abrons
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Thyroid Eye Disease
- Interventions
- Batoclimab, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 29
- States / cities
- Beverly Hills, California • Carlsbad, California • Los Angeles, California + 24 more
- Conditions
- Glaucoma Open-Angle Primary, Ocular Hypertension
- Interventions
- H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%
- Drug
- Lead sponsor
- D. Western Therapeutics Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more
- Conditions
- Refractory or Unexplained Chronic Cough
- Interventions
- NOC-110, Placebo
- Drug · Other
- Lead sponsor
- Nocion Therapeutics
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 455 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 68
- States / cities
- Foley, Alabama • Scottsdale, Arizona • Tempe, Arizona + 60 more
- Conditions
- Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- aflibercept, High-dose aflibercept
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 84
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 78 more
- Conditions
- Dry Eye Syndromes
- Interventions
- Intranasal Tear Neurostimulator
- Device
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Louisville, Kentucky • Memphis, Tennessee • Nashville, Tennessee
- Conditions
- Cystic Fibrosis
- Interventions
- 7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
- Drug
- Lead sponsor
- CF Therapeutics Development Network Coordinating Center
- Network
- Eligibility
- 4 Months to 59 Months
- Enrollment
- 321 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 24 more
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
- Interventions
- Ixo-vec, Aflibercept
- Genetic · Drug
- Lead sponsor
- Adverum Biotechnologies, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 79
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more